TT-232 Uses, Dosage, Side Effects and more
Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).
| Attribute | Details |
|---|---|
| Trade Name | TT-232 |
| Generic | TT-232 |
| Type | |
| Formula | C45H58N10O9S2 |
| Weight | Average: 947.14 Monoisotopic: 946.382965836 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
